346 related articles for article (PubMed ID: 12766847)
1. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y
Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847
[No Abstract] [Full Text] [Related]
2. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
Jandourek A; Brown P; Vazquez JA
Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
[No Abstract] [Full Text] [Related]
3. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
[TBL] [Abstract][Full Text] [Related]
4. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies.
Cesaro S; Rossetti F; Perilongo G; Rossi L; Zanesco L
Haematologica; 1993; 78(4):249-51. PubMed ID: 8294059
[TBL] [Abstract][Full Text] [Related]
6. Candida krusei fungemia. An escalating serious infection in immunocompromised patients.
Abbas J; Bodey GP; Hanna HA; Mardani M; Girgawy E; Abi-Said D; Whimbey E; Hachem R; Raad I
Arch Intern Med; 2000 Sep; 160(17):2659-64. PubMed ID: 10999981
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Myoken Y; Kyo T; Sugata T; Murayama SY; Mikami Y
Haematologica; 2006 Feb; 91(2):287-8. PubMed ID: 16461328
[TBL] [Abstract][Full Text] [Related]
9. Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome.
Krcméry V; Spánik S; Grausová S; Trupl J; Krupová I; Roidová A; Sálek T; Sufliarsky J; Mardiak J
Neoplasma; 1998; 45(5):336-42. PubMed ID: 9921924
[TBL] [Abstract][Full Text] [Related]
10. Emergence of Candida albicans fungemia during voriconazole therapy.
Mohammedi I; Thiebaut A; Piens MA; Argaud L; Martin O; Robert D
J Infect; 2005 Oct; 51(3):e83-4. PubMed ID: 16230209
[No Abstract] [Full Text] [Related]
11. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia.
Nolte FS; Parkinson T; Falconer DJ; Dix S; Williams J; Gilmore C; Geller R; Wingard JR
Antimicrob Agents Chemother; 1997 Jan; 41(1):196-9. PubMed ID: 8980781
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
Ghannoum MA; Kim HG; Long L
J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole resistance of Candida krusei.
Manso E; Montillo M; Discepoli G; Leoni P
Boll Ist Sieroter Milan; 1991-1992; 70(1-2):527-9. PubMed ID: 1670057
[TBL] [Abstract][Full Text] [Related]
14. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.
Rex JH; Pappas PG; Karchmer AW; Sobel J; Edwards JE; Hadley S; Brass C; Vazquez JA; Chapman SW; Horowitz HW; Zervos M; McKinsey D; Lee J; Babinchak T; Bradsher RW; Cleary JD; Cohen DM; Danziger L; Goldman M; Goodman J; Hilton E; Hyslop NE; Kett DH; Lutz J; Rubin RH; Scheld WM; Schuster M; Simmons B; Stein DK; Washburn RG; Mautner L; Chu TC; Panzer H; Rosenstein RB; Booth J;
Clin Infect Dis; 2003 May; 36(10):1221-8. PubMed ID: 12746765
[TBL] [Abstract][Full Text] [Related]
15. [Candida albicans fungemia with pulmonary localization treated with fluconazole. A case report].
Thomas F; Mebtouche B; Clavier H; Kalfon P
Rev Pneumol Clin; 2000 Feb; 56(1):37-40. PubMed ID: 10740113
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of the serum Candida antigen titer for initiation of antifungal therapy after post-remission chemotherapy in patients with acute leukemia.
Iwasaki H; Misaki H; Nakamura T; Ueda T
Int J Hematol; 2000 Apr; 71(3):266-72. PubMed ID: 10846834
[TBL] [Abstract][Full Text] [Related]
17. Candida lusitaniae infections in the era of fluconazole availability.
Hawkins JL; Baddour LM
Clin Infect Dis; 2003 Jan; 36(2):e14-8. PubMed ID: 12522762
[TBL] [Abstract][Full Text] [Related]
18. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
19. The prophylactic effectiveness of various antifungal agents against the progression of trichosporonosis fungemia to disseminated disease in a neutropenic mouse model.
Tokimatsu I; Kushima H; Hashinaga K; Umeki K; Ohama M; Ishii H; Kishi K; Hiramatsu K; Kadota J
Int J Antimicrob Agents; 2007 Jan; 29(1):84-8. PubMed ID: 17189098
[TBL] [Abstract][Full Text] [Related]
20. A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia.
Dalle F; Lafon I; L'ollivier C; Ferrant E; Sicard P; Labruère C; Jebrane A; Laubriet A; Vagner O; Caillot D; Bonnin A
Haematologica; 2008 Apr; 93(4):581-7. PubMed ID: 18322258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
